Assessment of the implementation of DOTS strategy in two chest facilities in Alexandria, Egypt

Eastern Mediterranean Health Journal

Volumn 13, Issue 5, 2007, Pages 1085-1097

  Elmahalli, A A ^a   Abdel Aziz, Basem Farouk ^a  

^a High Institute of Public Health Egypt   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; EGYPT; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; SHORT COURSE THERAPY; SPUTUM SMEAR; TUBERCULOSIS CONTROL;

EID: 37849032646     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2007.13.5.1085     Document Type: Article

References (43)

1. Brown JW. TB: keeping an ancient killer at bay. Medical laboratory observer, 2004, 36(11):8-17.
2. Global tuberculosis control: surveillance, planning, and financing. WHO report 2003. Geneva, World Health Organization, 2003 (WHO/CDS/TB/ 2003.316).
3. Dye C et al. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Journal of the American Medical Association, 1999, 282(7):677-86.
4. Chakraborty AK. Epidemiology of tuberculosis: current status in India. Indian journal of medical research, 2004, 120(4):248-76.
5. Treatment of tuberculosis: guidelines for national programmes. Geneva, World Health Organization, 2003 (WHO/CDS/TB/2003.313).
6. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet, 2002, 359(9308):775-80.
7. Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004 (WHO/HTM/ T-B/2004.334).
8. Global tuberculosis programme. Framework for effective tuberculosis control. Geneva, World Health Organization, 1994 (WHO/TB/94.179).
9. Sbarbaro J. What are the advantages of direct observation of treatment? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:183-4 (WHO/HTM/TB/2004.334).
10. Moore RD et al. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. American journal of respiratory and critical care medicine, 1996, 154(4 Pt 1):1013-9.
11. Weis SE et al. The effect of directly observed therapy resistance and relapse in tuberculosis. New England journal of medicine, 1994, 330(17):1179-84.
12. Gninafon M. The antituberculosis programme in Benin. Bulletin of the International Union against Tuberculosis and Lung Disease, 1990, 66(Suppl.):57-8.
13. Dye C et al. Evaluating the impact of tuberculosis control: number of deaths prevented by short-term chemotherapy in China. International journal of epidemiology, 2000, 29(3):558-64.
14. [No authors listed]. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet, 1996, 347(8998):358-62.
15. Zhang LX, Tu DH, Enarson DA. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. International journal of tuberculosis and lung disease, 2000, 4(10):904-10.
16. Arguello L. Results of the tuberculosis control programme in Nicaragua in 1984-1989. Bulletin of the International Union against Tuberculosis and Lung Disease, 1990, 66(Suppl.):51-2.
17. Norval PY et al. DOTS in Cambodia: directly observed treatment with short-course chemotherapy. International journal of tuberculosis and lung disease, 1998, 2(1):44-51.
18. Nyangulu DS, Nkhoma WN, Salaniponi FM. Factors contributing to successful tuberculosis control in Malawi. Bulletin of the International Union against Tuberculosis and Lung Disease, 1990, 66(Suppl.): 45-6.
19. Chum HJ. The Tanzania National Tuberculosis/Leprosy Programme in the face of HIV infection. Bulletin of the International Union against Tuberculosis and Lung Disease, 1990, 66(Suppl.):53-5.
20. Frieden T. What are examples of effective tuberculosis control programmes? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:318-21.
21. Corbett EL et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of internal medicine, 2003, 163(9):1009-21.
22. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet, 2004, 364(9432):417-22.
23. Bruchfeld J et al. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates from Ethiopian pulmonary tuberculosis patients with and without human immunodeficiency virus infection. Journal of clinical microbiology, 2002, 40(5):1636-43.
24. Frieden T. What are examples of effective tuberculosis control programmes? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:318-21.
25. Maher D, Raviglione M. Why is a recording and reporting system needed, and what system is recommended? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:270-3.
26. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva, World Health Organization, 2003 (WHO/CDA/TB/203.313).
27. What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. Geneva, World Health Organization, 1999 (WHO/ CDS/CPC/TB/99.270).
28. Global tuberculosis control. WHO report 2001. Geneva, World Health Organization, 2001 (WHO/CDS/TB/2001.287).
29. Espinal M, Frieden T. What are the causes of drug-resistant TB? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:207-8.
30. Schreuder B et al. Viewpoint: why and how tuberculosis control should be included in health sector reviews. Tropical medicine and international health, 2004, 9(8):910-6.
31. Public-private mix for DOTS: practical tools for implementation. Geneva, World Health Organization, 2003 (WHO/CDS/TB/2003.325).
32. Bhat S et al. Revised national tuberculosis control programme: an urban experience. Indian journal of tuberculosis, 1998, 45(4):207-10.
33. Davidson BL. A controlled comparison of directly-observed therapy vs self-administration therapy for active tuberculosis in the urban United States. Chest, 1998, 114:1239-43.
34. Tuberculosis and gender. Geneva, World Health Organization, 2005 (http://www.who.int/tb/dots/gender/en/, accessed 5 February 2007).
35. Knight L. Tuberculosis and sustainable development. Geneva, World Health Organization, 2000 (Stop TB Initiative series WHO/CDS/STB/2000.4).
36. Ahlburg D. The economic impact of tuberculosis. Geneva, World Health Organization, 2000 (WHO/CDS/STB/2000.5).
37. Luelmo F. What is the role of sputum microscopy in patients attending health facilities? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:7-10.
38. Raviglione M, Frieden T. What are examples of effective tuberculosis control programmes? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:318-21
39. Smith I. What are the global targets for tuberculosis control and what are the basis for these targets? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:226-9.
40. Fox W. General considerations on the choice and control of chemotherapy in pulmonary tuberculosis. Bulletin of the international journal of tuberculosis and lung disease, 1972, 47:51-71.
41. Toman K. What are the keys to cure? In: Frieden T, ed. Toman's Tuberculosis: case detection, treatment, and monitoring, 2nd ed. Geneva, World Health Organization, 2004:260-3.
42. Luelmo F, Frieden T. What are the indicators of an effective tuberculosis control programme? In: Frieden T, ed. Toman's tuberculosis: case detection, treatment and monitoring - questions and answers, 2nd ed. Geneva, World Health Organization, 2004:315-6 (WHO/ HTM/TB/2004.334).
43. Xu B et al. DOTS in China - removing barriers or moving barriers? Health policy and planning, 2006, 21(5):365-72.